24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Richard Francis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:12
Navan to file confidentially for IPO, betting on market reopening
16:13
Israel delivers economic decapitation strike on Iranian regime
10:57
Israeli Mossad established combat drone bases on Iranian soil
07:05
Israel strikes Iran's nuclear sites and military commanders in major attack
More stories
Buzz
Most popular
Daily
Weekly
1
Intel to cut jobs at Kiryat Gat fab, says it must “position our business for the future”
2
Rinki Sethi, former Twitter CISO, joins cloud security startup Upwind
3
Navan to file confidentially for IPO, betting on market reopening
4
Andreessen Horowitz targets elite IDF alumni for startup accelerator
5
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
More news
Richard Francis
3 stories about Richard Francis
Teva surpasses expectations in Q4 but sets cautious outlook for 2025
29.01.25
|
Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
Teva soars with double-digit growth in Q3, raises annual forecast
06.11.24
|
Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
Teva CEO: "The company played not to lose, now we’ll play to win"
21.02.24
|
Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory
